{
    "clinical_study": {
        "@rank": "40170", 
        "acronym": "ELAN-UNFIT", 
        "arm_group": [
            {
                "arm_group_label": "Cetuximab", 
                "arm_group_type": "Experimental", 
                "description": "Dosing schedule: 500 mg/m\u00b2, every two weeks (q2w) Mode of administration: IV"
            }, 
            {
                "arm_group_label": "Methotrexate", 
                "arm_group_type": "Active Comparator", 
                "description": "Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV"
            }
        ], 
        "brief_summary": {
            "textblock": "To test whether cetuximab improves efficacy/tolerance as compared to methotrexate in first\n      line treatment of unfit patients \u00b3 70 years old with recurrent and /or metastatic HNSCC.\n      Efficacy assessed by failure free survival"
        }, 
        "brief_title": "Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Head Neck Cancer Squamous Cell Recurrent", 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Neoplasms, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 70 or over\n\n          -  Included in ELAN-ONCOVAL study and considered as \"Unfit\" by geriatric evaluation done\n             in this study\n\n          -  PS < 3\n\n          -  Histologically confirmed diagnosis of squamous cell carcinoma of head and neck: oral\n             cavity, oropharynx, hypopharynx, larynx.\n\n          -  Recurrence and/or metastatic disease not suitable for local therapy.\n\n          -  At least one measurable lesion (RECIST 1.1) by CT or MRI.\n\n          -  No brain metastasis.\n\n          -  Clearance of creatinine >= 50ml/mn (MDRD).\n\n          -  Adequate haematological functions defined as follows: absolute neutrophil count > 1.5\n             x 109/l, platelet > 100 x 109/l, hemoglobin >= 9.5 g/dl\n\n          -  Adequate hepatic functions with serum total bilirubin <1.25 Upper limit of normal\n             range (ULN); SGOT/SGPT < 5 ULN; AP < 5 ULN\n\n          -  Life expectancy > 12 weeks.\n\n          -  Males of reproductive potential must agree to use an effective contraceptive method\n             during the treatment and after the end of treatment during five months.\n\n          -  Signed informed consent.\n\n          -  Affiliated to Health Insurance regimen (according to Public Health Law of August 9,\n             2004).\n\n        Exclusion Criteria:\n\n          -  Included in ELAN-ONCOVAL study and considered as \"Fit\" by geriatric evaluation\n\n          -  Patients with nasopharyngeal cancer, paranasal sinus, or cervical lymph nodes\n             metastasis of unknown origin.\n\n          -  Prior systemic chemotherapy for the squamous cell carcinoma of head and neck, except\n             if given as part of a multimodal treatment for locally advanced disease which was\n             completed more than 6 months prior to study entry.\n\n          -  Prior anti-EGFR therapy.\n\n          -  Surgery (excluding prior diagnostic biopsy) or irradiation within 4 weeks before\n             study entry.\n\n          -  Brain metastasis\n\n          -  Active infection including tuberculosis and HIV infection.\n\n          -  Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or\n             IV), unstable angina pectoris, history of myocardial infarction within the last\n             twelve months, significant arrhythmias\n\n          -  Concomitant immunotherapy or antitumoral hormonotherapy.\n\n          -  Requirement for treatment with any of the prohibited concomitant medications listed\n             in SPC of Cetuximab and Methotrexate. In particular, acetylsalicylic acid used at\n             analgesic, antipyretic or anti-inflammatory doses (see Section 6.3.2).\n\n          -  Malignancies within 5 years prior to randomization, with the exception of adequately\n             treated basal or squamous cell skin cancer and carcinoma in situ of the cervix\n\n          -  Known allergic hypersensitivity to cetuximab and/or methotrexate or any of their\n             excipients.\n\n          -  Other severe acute or chronic psychiatric or medical condition, or significant\n             laboratory abnormality requiring further investigation that may cause undue risk for\n             the patient's safety, inhibit protocol participation, or interfere with\n             interpretation of study results, and in the judgment of the investigator would make\n             the patient inappropriate for entry into this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "164", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884623", 
            "org_study_id": "2012-004967-38", 
            "secondary_id": "2012/1937"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cetuximab", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Methotrexate", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "contact": {
                "email": "joel.guigay@gustaveroussy.fr", 
                "last_name": "Jo\u00ebl GUIGAY, Pr", 
                "phone": "0142116536", 
                "phone_ext": "+33"
            }, 
            "contact_backup": {
                "email": "anne.auperin@gustaveroussy.fr", 
                "last_name": "Anne AUPERIN, MD", 
                "phone": "0142115499", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Institut Gustave Roussy"
            }, 
            "investigator": {
                "last_name": "Joel GUIGAY, Pr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation", 
        "overall_contact": {
            "email": "joel.guigay@gustaveroussy.fr", 
            "last_name": "Joel GUIGAY, Pr", 
            "phone": "0142116536", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "anne.auerin@gustaveroussy.fr", 
            "last_name": "Anne AUPERIN, MD", 
            "phone": "0142445499", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Joel GUIGAY, Pr", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite criteria of efficacy and tolerance: Failure free survival (FFS) defined as time from randomization to the first event among progression (defined by RECIST criteria), treatment stop (whatever the cause), loss of 2 points or more in Activities in Daily Living (ADL) scale and death (whatever the cause). Patients who don't have any of these events are censored at the date of last follow-up.", 
            "measure": "Failure free survival (FFS)", 
            "safety_issue": "No", 
            "time_frame": "From randomization to the first event among progression, treatment stop, whatever the cause, loss of 2 points or more in ADL scale and death assessed up to 16 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884623"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients with disease progression will be treated off protocol but will be followed for overall survival evaluation.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From randomization to death from any cause assessed up to 1 months"
            }, 
            {
                "description": "minimum time from randomization to progression as defined by RECIST criteria or to death from any cause.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From randomization to progression assessed up to 16 months"
            }
        ], 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute, France", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ligue contre le cancer, France", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Merck Serono International SA", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}